Clinical Trials Logo

Filter by:
NCT ID: NCT06018896 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

PTCA199-4
Start date: August 25, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.

NCT ID: NCT06018883 Recruiting - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

PTCA199-3
Start date: August 20, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of low-dose vitamin C on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

NCT ID: NCT06018870 Recruiting - Glioma Clinical Trials

MRI Contrast Clearance Analysis for Glioma Grading and Genotyping

Start date: June 1, 2023
Phase:
Study type: Observational

Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 2021 World Health Organization (WHO) classification of tumors for the central nervous system, glioma genotyping was considered the most relevant information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are two essential molecular markers that divide glioma into three groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q codeletion. MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map, Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue (delayed signal<early signal), while red/nontumor regions in CCA represent contrast accumulation (delayed signal>early signal). However, there are not any reports on the role of MRI CCA in glioma grading and genotyping, Thus, We hypothesized that the proportion of blue/red region and their histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q codeletion in gliomas, and to assess the application of CCA in glioma grading.

NCT ID: NCT06018831 Recruiting - Kidney Diseases Clinical Trials

Urine and Ultrasound Screening for Kidney Disease in Children

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to early detect kidney disease in the natural population cohort of children by urine and ultrasound screening, to assist in the precise prevention and treatment of children's kidney disease, and to establish a risk prediction system for children's kidney disease. About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Through the project, child who is found with abnormal urine or ultrasound result will be referred to Children's Hospital of Fudan University to get further examination and treatment.

NCT ID: NCT06018714 Recruiting - Clinical trials for Colorectal Cancer Metastatic

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

The overall 5-year survival rate for patients with colorectal liver metastases (CRLM) is still less than 20%. Surgery-based local treatment can achieve no evidence of disease (NED) in CRLM patients, but over 60% of patients experience recurrence even after achieving NED. Even with adjuvant therapy for the 6-month perioperative period after achieving NED, the recurrence rate remains high. Fruquintinib is a selective anti-angiogenic inhibitor that may help reduce tumor recurrence and prolong the time to recurrence and metastasis. The Chinese Society of Clinical Oncology (CSCO) guidelines have recommended fruquintinib as a third-line therapy for colorectal cancer. This study aims to evaluate the effectiveness and safety of fruquintinib as a maintenance therapy for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy.

NCT ID: NCT06018506 Recruiting - Clinical trials for Hematologic Malignancy

A Phase I Study of BR108 in Hematological Malignancies

Start date: March 27, 2023
Phase: Phase 1
Study type: Interventional

A Phase I study of BR108 in hematological malignancies

NCT ID: NCT06018493 Recruiting - Hypertension Clinical Trials

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

NCT ID: NCT06018363 Recruiting - Brain Gliomas Clinical Trials

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR-γδ T cells) in relapsed and refractory B7H3 Positive malignant brain glioma.The main purpose of this study was to evaluate the safety and feasibility of CAR-γδ T cell infusion in patients with relapsed and refractory B7H3 Positive malignant brain glioma.

NCT ID: NCT06018337 Recruiting - Clinical trials for Metastatic Breast Cancer

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Start date: January 18, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population.

NCT ID: NCT06018246 Completed - Clinical trials for Gastrointestinal Cancer

Nutritional Risk Screening Nutritional Support Gastrointestinal Cancer

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to compare the effects of different nutritional support methods based on nutritional risk screening on postoperative nutritional status in patients with gastrointestinal tumors.The main question it aims to answer is that different types of nutrition can improve the nutritional status of patients with different nutritional status;Long-term dietary interventions for patients with poor nutrition can make cancer patients better able to tolerate surgery and chemotherapy and improve their quality of life.The intervention group received nutrition + exercise + psychological intervention upon admission, routine parenteral and enteral nutrition support after operation, and continued nutrition + exercise + psychological intervention after discharge.The control group received routine parenteral nutrition support in the department after surgery, and the patients and their families were given diet education during hospitalization.